+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are studying the long-term safety, tolerability, and effectiveness of remibrutinib in adults with moderate to severe hidradenitis suppurativa who have finished previous Phase 3 studies. This global Phase 3 extension trial continues to evaluate remibrutinibs impact over several years, fulfilling commitments to provide continued access to the treatment. Participants will continue their assigned blinded dose of remibrutinib from the prior studies until final analysis or dose adjustment. Afterward, treatment shifts to an open-label phase, lasting until commercial availability, reimbursement, alternative access, or four years of extension treatment are completed. Those ending treatment early or not transitioning to commercial remibrutinib enter a four-week safety follow-up without treatment. Throughout the study, participants undergo regular monitoring for adverse events and treatment responses using scales such as the International Hidradenitis Suppurativa Severity Score System and clinical response measures up to week 276. The study emphasizes safety and long-term effects, with participation lasting up to several years including follow-up, ensuring comprehensive data collection on remibrutinibs use in this condition.

Age: 18Years - 100YearsAll GendersPhase 3
44 locations
P

Actively Recruiting

This research is a rollover study for participants who have previously taken part in specific Incyte-sponsored clinical trials involving the drug povorcitinib, aimed at treating Hidradenitis Suppurativa HS. The purpose is to continue evaluating the treatments safety and tolerability over an extended period, building on prior studies. Participants must have completed treatment in the original trials without major safety concerns and shown clinical benefits. Participants will continue to receive povorcitinib orally, following the same dosing schedule and options as in their original parent study. This ongoing treatment phase allows researchers to monitor long-term effects and gather extended safety data. The study is designed as a single-group phase 3b trial focused on treatment. Throughout the study, participants will be regularly monitored for treatment-emergent adverse events over approximately three years. Researchers will also assess specific clinical measures at each visit to evaluate treatment impact. Participants are expected to comply with study procedures, including avoiding pregnancy or fathering children as outlined. The total participation duration extends up to about three years, with regular visits to track safety and treatment outcomes.

Age: 18Years +All GendersPhase 3
306 locations